Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Windtree Therapeutics, Inc. (WINT : NSDQ)
 
 • Company Description   
Windtree Therapeutics, Inc. is a biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. The company's proprietary technology platform includes a synthetic, peptide-containing surfactant that is structurally similar to endogenous pulmonary surfactant and novel drug-delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant. Windtree Therapeutics, Inc., formerly known as Discovery Laboratories Inc., is based in Warrington, Pennsylvania.

Number of Employees: 33

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.57 Daily Weekly Monthly
20 Day Moving Average: 303,174 shares
Shares Outstanding: 29.41 (millions)
Market Capitalization: $16.73 (millions)
Beta: 0.29
52 Week High: $3.40
52 Week Low: $0.48
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -29.74% -23.06%
12 Week -46.32% -39.67%
Year To Date -64.55% -56.69%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2600 KELLY ROAD SUITE 100
-
WARRINGTON,PA 18976
USA
ph: 215-488-9300
fax: 215-488-9301
ir@windtreetx.com None
 
 • General Corporate Information   
Officers
Craig E. Fraser - Chief Executive Officer and President
James Huang - Chairman
John P. Hamill - Senior Vice President and Chief Financial Officer
Daniel E. Geffken - Director
Evan Loh - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 97382D303
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 29.41
Most Recent Split Date: 4.00 (0.33:1)
Beta: 0.29
Market Capitalization: $16.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.68 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.47
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 43.14%
vs. Previous Quarter: 36.96%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -145.63
12/31/21 - -112.63
09/30/21 - -92.64
ROA
03/31/22 - -84.17
12/31/21 - -70.05
09/30/21 - -58.49
Current Ratio
03/31/22 - 3.46
12/31/21 - 4.77
09/30/21 - 5.13
Quick Ratio
03/31/22 - 3.46
12/31/21 - 4.77
09/30/21 - 5.13
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.22
12/31/21 - 1.48
09/30/21 - 1.88
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.43
12/31/21 - 0.36
09/30/21 - 0.30
Debt-to-Capital
03/31/22 - 30.16
12/31/21 - 26.37
09/30/21 - 23.01
 

Powered by Zacks Investment Research ©